Review Article
Vitamin Supplementation as Possible Prophylactic Treatment against Migraine with Aura and Menstrual Migraine
Table 1
Clinical trials conducted among migraine patients using riboflavin (vitamin B2).
| Study location | Control | Placebo |
Duration of administration | Outcomes | value | Reference | Dose | Sample size | Dose | Sample size |
| Belgium | B2 (400 mg/day) | 55 | Placebo | 55 |
3 months | 59% of reduction in frequencies of migraine attack and days with headache | 0.0120 | [36] |
| USA | B2 (400 mg/day) + magnesium = (300 mg/day) + feverfew (100 mg/day) | 24 | 25 mg/day of vitamin B2 | 24 |
3 months | 50% or greater reduction in migraine in 40% of migraine patients | 0.0006 | | Days with migraine | 0.0700 | [45] | Migraine index | 0.0006 | |
| USA | B2 (400 mg/day) + magnesium = (300 mg/day) + feverfew (100 mg/day) | 24 | 25 mg/day of vitamin B2 | 24 |
1 month | 50% or greater in reduction of migraine in 33% of migraine patients | <0.0001 | | Days with migraine | 0.0400 | [45] | Migraine index | 0.1000 | |
| Australia | B2 = 200 mg/day | 21 | Placebo | 27 |
1 month | 50% or greater reduction in headaches | 0.1250 | [46] |
| Italy | B2 (200 mg/day or 400 mg/day) randomly administered | 41 | Compared with baseline | |
6 months | 50% or greater reduction in headache frequency among 68.4% of patients 50% or greater reduction in intensity of headache | <0.010 | [47] |
| Netherlands | B2 (50 mg/day) | 42 | Placebo | 42 | | Reduction in frequency of migraine attacks | 0.4400 | [48] |
| Germany | B2 (400 mg/day) | 23 | Compared with baseline | |
3 months | Frequency of headache | <0.0010 | | Duration of attacks | 0.0980 | [37] | Headache intensity | 0.2960 | |
| Germany | B2 (400 mg/day) | 23 | Compared with baseline | |
6 months | Frequency of headache | 0.0050 | | Duration of attacks | 0.0980 | [37] | Headache intensity | 0.2960 | |
|
|